摘要
目的探讨钠-葡萄糖协同转运蛋白2(sodium-glucose linked transporters-2,SGLT-2)抑制剂达格列净辅助治疗对糖尿病肾病患者肾功能指标及血糖水平的影响。方法选取2018年3月至2020年3月广东医科大学附属惠东医院接受治疗的80例糖尿病肾病患者作为研究对象,按照随机数字表法分为对照组和观察组,每组40例。其中,对照组给予马来酸依那普利,观察组给予马来酸依那普利+达格列净,两组均持续治疗12周后观察患者肾功能、血糖水平、临床疗效、炎性因子水平和不良反应。结果观察组血肌酐(serum creatinine,Scr)、尿素氮(blood urea nitrogen,BUN)、尿微量白蛋白(urine microalbumin,UmAlb)水平均明显低于对照组,差异有统计学意义(t=4.314、4.279、14.514,P<0.05);观察组治疗后空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2 h postprandial blood glucose,2hPG)水平低于对照组,临床治疗总有效率高于对照组,差异有统计学意义(t=13.392、14.247,χ^(2)=5.000,P<0.05);与对照组比较,治疗后观察组白介素6(interleukin-6,IL-6)、白介素8(interleukin-8,IL-8)水平和不良反应发生率均低于对照组,差异有统计学意义(t=29.569、10.181,χ^(2)=4.114,P<0.05)。结论辅助应用SGLT-2抑制剂达格列净对糖尿病肾病患者进行治疗,可在一定程度上改善患者的肾功能,控制患者的血糖,减轻其炎性反应,同时还能提升治疗的安全性,有助于进一步提高患者的临床治疗效果。
Objective To determine the effect of sodium-glucose linked transporters-2(SGLT-2),a sodium-glucose co-transporter inhibitor,on renal function and blood glucose in diabetic nephropathy patients.Methods Eighty patients with diabetic nephropathy who received treatment at Huidong Hospital Affiliated to Guangdong Medical University from March 2018 to March 2020 were selected as research subjects.The patients were divided into control and observation groups according to the random number table method,with 40 patients in each group.Both groups were treated for 12 weeks.Renal function,the blood glucose level,clinical efficacy,inflammatory factors,and adverse reactions were recorded.Results The serum creatinine(Scr),blood urea nitrogen(BUN),and urine microalbumin(UmAlb)levels in the observation group were significantly lower than the control group(t=4.314,4.279,and 14.514,respectively;all P<0.05).The fasting blood glucose(FBG)and 2 h postprandial blood glucose(2 hPG)levels in the observation group were lower than the control group,and the total clinical treatment efficacy rate was higher than the control group(t=13.392,14.247,χ^(2)=5.000;all P<0.05).The interleukin-6(IL-6)and IL-8 levels and the incidence of adverse reactions in the observation group after treatment were significantly lower than the control group(t=29.569,10.181,χ^(2)=4.114;all P<0.05).Conclusion Adjuvant application of the SGLT-2 inhibitor,dagliazin,in the treatment of diabetic nephropathy can improve renal function,control the blood glucose,and reduce the inflammatory response,but also improve treatment safety,which will further facilitate improvement in the clinical treatment effect of patients.
作者
曾洁纯
ZENG Jie-chun(Department of Nephrology and Endocrinology,Huidong Hospital Affiliated to Guangdong Medical University,Huizhou,Guangdong 516300,China)
出处
《慢性病学杂志》
2022年第1期73-76,共4页
Chronic Pathematology Journal
